SIRION Biotech expands operations with new office in Cambridge, Massachusetts

SIRION Biotech International Inc., a leading provider of custom viral vectors for preclinical and clinical studies, has officially opened a new office in Cambridge, Massachusetts. The move signals the company’s growing commitment to advancing gene therapy in the United States, a market where two-thirds of its revenue already comes from. The new location, situated at 125 Cambridgepark Drive, Suite 301, was celebrated with a grand opening event hosted at the Forsyth Institute, a key hub for gene therapy innovation in the region.

A milestone for SIRION Biotech in the US

SIRION’s expansion to Cambridge is not just about a new office—it’s about establishing a stronger foothold in the heart of one of the most renowned life science hubs in the world. The event, a Bavarian-themed gathering, brought together experts in the gene therapy and viral vector industries, highlighting the importance of these technologies in making gene therapies a clinical reality. Renowned scientists and industry leaders discussed the critical role of viral vectors in advancing gene therapies, a sector that has seen tremendous clinical progress.

Dieter Lingelbach, Chief Operating Officer of SIRION Biotech, emphasised the company’s dedication to the US market, noting that the opening of a local office in Cambridge would enable them to better support their current partners and attract new collaborations. “Since two-thirds of SIRION’s revenue already comes from US customers and partners, opening an office in a Life Science hub like Cambridge further demonstrates our commitment to supporting existing customers and further expanding into the US market,” said Lingelbach.

Key partnerships and future prospects

The opening of SIRION’s new office comes on the heels of several important collaborations with major players in gene therapy, including Denali Therapeutics and Orchard Therapeutics. SIRION has also secured an undisclosed alliance with a prominent public company advancing gene therapy innovations. These partnerships highlight the increasing demand for high-quality viral vectors, which are critical to the transduction and manufacturing processes in gene therapy.

Gene therapy has made impressive strides in clinical research, and SIRION’s custom viral vectors are playing an integral role in driving these advances. As the company continues to grow its portfolio and expertise, the opening of this office strengthens its position as a key partner in the gene therapy field.